Funding Support and Author Disclosures The EXCELLENT trial is sponsored by CellProthera. Dr Henon is a founder and shareholder of CellProthera. Dr Trebuchet, Mr de Kalbermatten, and Dr Ibon Garitaonandia are staff members of CellProthera. Drs Roncalli, Marie, Bhatt, Solomon, Montalescot, and Zannad have received fees from CellProthera as members of the steering committee of the EXCELLENT trial. Dr Roncalli has been an advisory board member and has received consulting fees from CellProthera. Dr Zannad has received personal fees from Applied Therapeutics, Bayer, Biopeutics, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, Cardior, Cereno Pharmaceutical, CellProthera, Merck, Northsea, Novartis, NovoNordisk, Otsuka, Owkin, has stock options at G3Pharmaceutical and equities at Cereno Pharmaceutical, Cardiorenal, Eshmoun Clinical Research, and is the founder of Cardiovascular Clinical Trialists (CVCT). Dr Bhatt is on the advisory boards of AngioWave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, and Stasys; is on the board of directors of the American Heart Association–New York City; is on the board of directors and has stock options with AngioWave, Bristol Myers Squibb, and DRS.LINQ; is on the board of directors and owns stock in High Enroll; has served as a consultant for Broadview Ventures, GlaxoSmithKline, Hims, SFJ, and Youngene; has been on the data monitoring committee for Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (as chair of the PEITHO trial), the Cleveland Clinic, Contego Medical (as chair of PERFORMANCE 2), Duke Clinical Research Institute, the Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial funded by Daiichi Sankyo; for the ABILITY-DM trial funded by Concept Medical; for ALLAY-HF funded by Alleviant Medical), Novartis, the Population Health Research Institute, and Rutgers University (for the National Institutes of Health–funded MINT trial); has received honoraria from the American College of Cardiology (as senior associate editor of clinical trials and news, ACC.org; and as chair of the ACC Accreditation Oversight Committee), the Arnold and Porter law firm (for work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute for the RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; and the AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (as editor in chief of the Harvard Heart Letter), the Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (for the AHA lecture), Cowen and Company, the Duke Clinical Research Institute (for clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (as editor in chief of the Journal of Invasive Cardiology), the Journal of the American College of Cardiology (as guest editor and associate editor), K2P (as co-chair of the interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (for CME steering committees), MJH Life Sciences, Oakstone CME (as course director of the Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee); and has received other renumeration from Clinical Cardiology (deputy editor); holds a patent for sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women’s Hospital who assigned it to Lexicon; neither I nor Brigham and Women’s Hospital receives any income from this patent); has received research funding from Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, the Medicines Company, Youngene, 89Bio; has received royalties from Elsevier (as editor for Braunwald’s Heart Disease); has served as site co-investigator for Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, and Vascular Solutions; has been a trustee for the American College of Cardiology; and has performed unfunded research for FlowCo. Dr Montalescot has received research funds for the institution or consulting/lecture fees from Abbott, Acutebio, Amgen, Boehringer Ingelheim, Celecor, Cell Prothera, Corflow, Hexacath, Idorsia, Merck Sharp & Dohme, Novo Nordisk, Sanofi, and SMT. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.